BioInvent, Genentech complete patient enrollment in BI-204 study
Developed in collaboration with Genentech, BI-204 is a monoclonal antibody targeting oxidised forms of low-density lipoprotein cholesterol. In the randomized placebo controlled double-blind multicenter Phase IIa study, BI-204
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.